US OptionsDetailed Quotes
AMRX241220P15000
- 0.00
- 0.000.00%
15min DelayClose Nov 27 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover0.00%IV-79.64%PremiumDec 20, 2024Expiry Date6.65Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.29Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Amneal Pharmaceuticals Stock Discussion
Amneal Resubmits Dhe Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, Its First Generic Injectable GLP-1 Agonist
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
5 MINUTES AGO, 6:00 AM EDT
VIA BUSINESSWIRE
Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing network to ensure supply of Metsera's portfolio of novel injectable and oral development programs, including GLP-1 and amylin receptor agonists
Agreement provides Amneal w...
Amneal and Shilpa Announce U.S. FDA Approval of Boruzu™, the First Ready-to-Use Version of Bortezomib for Subcutaneous Administration
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials! expects launch in Q4
Amneal Pharmaceuticals, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). This novel formulation promises to address some of the longstanding cha...
No comment yet